Metformin and Breast Cancer: A Literature Review

Document Type


Publication Date



Breast cancer is one of the prevalent forms of cancer in American women, accounting for nearly 41,000 deaths each year. While survival rates are improving, researchers continue to evaluate the efficacy of new treatment options. Metformin, a drug typically used to treat type 2 diabetes, has recently drawn attention for its potential as an anticancer therapeutic-demonstrating antiproliferative activity both in vitro and in vivo. Though the clinical trial results involving metformin as a cancer treatment have tended toward favorable, it has yet to be approved by the Food and Drug Administration as a treatment for breast cancer. The following literature review evaluates the current research and clinical trials involving metformin as a neoadjuvant treatment option for breast cancer.

First Advisor

William Schweinle

Research Area

Physician Assistant Studies

This document is currently not available here.